Life Technologies Acquires BAC BV, Expands Capabilities in Bioprocessing

   Life Technologies Acquires BAC BV, Expands Capabilities in Bioprocessing

New product line complements Life's current offerings, expands protein
purification workflow

PR Newswire

CARLSBAD, Calif., Jan. 22, 2013

CARLSBAD, Calif., Jan. 22, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced its acquisition of BAC BV, a privately held
company based in the Netherlands, and a leader in the discovery, development
and manufacture of protein purification products. The acquisition expands
Life's capabilities and product offerings in the growing market of
biopharmaceutical research and manufacturing.

"Our acquisition of BAC BV positions Life Technologies as a leading provider
of end-to-end solutions that are widely utilized in the bioprocess workflow,"
said Tony Hunt, head of BioProduction at Life Technologies. "Combining BAC's
current portfolio and pipeline with our pre-existing portfolio expands Life's
product offering and enables us to compete more fully across the protein
purification market. We intend to immediately integrate the portfolios and
leverage the Life commercial platform to drive accelerated growth in this

Bioprocessing is the production and analytical testing of biologically-based
therapeutics, which are developed in cultured cells or microorganisms, and
include drugs, vaccines, biosimilars, and gene and cell therapies. Life
Technologies' Gibco® brand is the market leader in cell culture media, a
position it has held for 50 years, and the company more recently integrated
its POROS® brand of chromatography resins for purification of therapeutic
products into the Bioproduction portfolio.

The acquisition expands Life's existing portfolio by adding BAC BV's unique
set of innovative and proprietary affinity ligands to the company's
world-class POROS® resins. Affinity ligands are molecules capable of binding
with very high affinity to specific proteins, and are typically attached to
chromatography resins in a production-scale, bio-purification process.

Life customers will benefit from a streamlined approach to protein
purification with tailored end-to-end solutions. In addition to Gibco® culture
media, POROS® resins and the BAC BV affinity ligand portfolio for protein
purification, Life also offers the Applied Biosystems® SEQ rapid molecular
kits for contaminant and impurity testing of bio-therapeutic products.

"We are looking forward to developing and providing unique, enabling products
from our combined portfolios and capabilities to our purification customers,"
said Laurens Sierkstra, Ph.D., chief executive officer of BAC BV. Sierkstra
and an additional 34 employees will join Life Technologies. Current BAC BV
facilities, a manufacturing site in Naarden and R&D facility in Leiden,
Netherlands, will remain in operation.

Financial terms of the deal were not disclosed. The tuck-in acquisition of BAC
BV is expected to be neutral to the company's overall ROIC three years after

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum, with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied
Biosystems®,Invitrogen™, Gibco®, Ambion®, Molecular Probes® and Novex®.Life
Technologiesemploys approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of$3.7 billionin 2011. Visit us at our

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact
Suzanne Clancy
858-205-4235 (mobile)

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.